2022
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis And Related Disorders 2022, 68: 104143. PMID: 36031693, PMCID: PMC9772048, DOI: 10.1016/j.msard.2022.104143.Peer-Reviewed Original ResearchConceptsEfficacy of ocrelizumabMultiple sclerosisImmunologic biomarkersClinical trialsTransient B-cell depletionClinical multiple sclerosisCSF immune cellsEffects of ocrelizumabMS disease pathophysiologyNew brain lesionsOvert neurological symptomsB-cell depletionPlacebo-controlled studyPhase 4 studyLong-term outcomesPatient-reported outcomesPrimary progressive MSHumanized monoclonal antibodyFirst-degree relativesB cell biologySubtle cognitive impairmentEligible patientsImmune recoveryProgressive MSWeek 48
2018
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization
Fuchs A, Gliwiński M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Gołab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grześ D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers In Immunology 2018, 8: 1844. PMID: 29379498, PMCID: PMC5775516, DOI: 10.3389/fimmu.2017.01844.Peer-Reviewed Original ResearchAntigen-presenting cellsRegulatory cellsTolerogenic antigen-presenting cellsT regulatory (Treg) cellsClinical applicationPosttransplant complicationsTreg preparationsAllergic diseasesClinical trialsTregsEfficacious treatmentTreg productsCellular therapyStandardized reportingMedicinal productsDifferent preparationsCellsInvestigatorsCD4ComplicationsTherapyDiseaseTrials
2017
Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment
Lucca LE, Hafler DA. Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. Journal Of Clinical Investigation 2017, 127: 1218-1220. PMID: 28319049, PMCID: PMC5373854, DOI: 10.1172/jci93565.Peer-Reviewed Original ResearchConceptsT cellsRecruitment of CD8Antitumor immune responseT cell recruitmentMigration of CD8Cell lung tumorsSyngeneic gliomaChemokines CXCL9Tumor escapeTumor controlImmune infiltrationMetastatic melanomaClinical trialsMalignant gliomasExpression of STAT1Immune surveillanceLung tumorsImmune responseAggressive cancerCell recruitmentCD8Tumor destructionTumorsGliomasCommon mutations
2010
A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis
Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S. A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis. JAMA Neurology 2010, 67: 1055-1061. PMID: 20837847, PMCID: PMC2954052, DOI: 10.1001/archneurol.2010.222.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdrenergic beta-AgonistsAdultAlbuterolDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleGlatiramer AcetateHumansInterferon-gammaInterleukin-13Logistic ModelsMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingOdds RatioPeptidesPilot ProjectsTreatment OutcomeConceptsMultiple Sclerosis Functional CompositeRelapsing-remitting multiple sclerosisGlatiramer acetateMultiple sclerosisClinical trialsAlbuterol groupTime pointsOral doseIL-13Subcutaneous injectionHelper T-cell subtypes 1Double-masked clinical trialGlatiramer acetate treatmentImmunologic end pointsMasked clinical trialEffects of albuterolIL-12 expressionIL-13 productionStudy time pointsΒ2-adrenergic agonistAlbuterol treatmentAcetate therapyAdverse eventsFirst relapseImmunologic effects
2007
Cytokines and interventional immunology
Hafler D. Cytokines and interventional immunology. Nature Reviews Immunology 2007, 7: 423-423. DOI: 10.1038/nri2101.Peer-Reviewed Original Research
1992
T cell vaccination in multiple sclerosis: A preliminary report
Hafler D, Cohen I, Benjamin D, Weiner H. T cell vaccination in multiple sclerosis: A preliminary report. Clinical Immunology 1992, 62: 307-313. PMID: 1541056, DOI: 10.1016/0090-1229(92)90108-z.Peer-Reviewed Original ResearchConceptsT cell clonesMultiple sclerosisAutoimmune diseasesCell clonesAutologous T cell clonesAutoreactive T cell clonesAutologous mixed lymphocyte responseProgressive multiple sclerosisExperimental autoimmune diseasesT cell vaccinationFurther clinical trialsMixed lymphocyte responseUntoward side effectsCentral nervous systemPhase one trialsCell vaccinationMyelin autoantigensImmunologic effectsLymphocyte responsesClinical trialsImmunologic studiesAutoreactive clonesCerebrospinal fluidSide effectsNervous system
1988
Immunotherapy of multiple sclerosis
Weiner H, Hafler D. Immunotherapy of multiple sclerosis. Annals Of Neurology 1988, 23: 211-222. PMID: 3288084, DOI: 10.1002/ana.410230302.Peer-Reviewed Original ResearchConceptsMultiple sclerosisClinical trialsHelper/inducer cellsOnset of progressionMultiple sclerosis therapyNumber of relapsesPresent treatment modalitiesAntigen-specific cellsActivated T cellsImmune balanceImmunotherapeutic interventionsNonspecific immunosuppressionSclerosis therapyAcute attacksAutoimmune diseasesInducer cellsLymphocyte trafficTreatment modalitiesSuppressor influencesEarly treatmentT cellsEffective treatmentTherapeutic goalsImmunotherapyImmune system